Literature DB >> 21239746

Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial.

Jin-Shei Lai1, Jennifer L Beaumont, Sarika Ogale, Paul Brunetta, David Cella.   

Abstract

OBJECTIVE: Fatigue is a common symptom of systemic lupus erythematosus (SLE). Our objective was to validate the 13-item Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale in patients with SLE.
METHODS: The FACIT-Fatigue, Medical Outcomes Study Short-Form-36 (SF-36) questionnaire, Brief Pain Inventory (BPI), and Patient Global Assessment Visual Analog Scale (Patient-GA) were completed at baseline and at Weeks 12, 24, and 52 by patients with moderately to severely active extrarenal SLE. The patients were participating in a rituximab clinical trial. The British Isles Lupus Assessment Group (BILAG) disease activity index and the Physician Global Assessment Visual Analog Scale (Physician-GA) were completed by physicians at the same visits.
RESULTS: At baseline, 254 patients completed the FACIT-Fatigue scale. Cronbach's α was > 0.95 at all visits. In cross-sectional analyses, FACIT-Fatigue scores differentiated between groups defined by BILAG General domain ratings. FACIT-Fatigue had moderate-high correlations (r = 0.5-0.8) with SF-36, BPI, and Patient-GA, but poor correlations with BILAG total score and Physician-GA (r = 0.1-0.3). At Weeks 12, 24, and 52, mean FACIT-Fatigue scale improvement was higher in patients who improved versus those who remained unchanged on the BILAG General domain. FACIT-Fatigue scale scores remained stable for patients with worsened BILAG General domain ratings compared to baseline. Distribution and anchor-based estimates suggested a minimally important difference (MID) range of 3-6 points.
CONCLUSION: The FACIT-Fatigue scale is a valid and responsive measure of fatigue in patients with SLE. MID in this SLE sample is similar to that derived previously in other populations. Since few patients experienced worsening BILAG General and Musculoskeletal domains in this study, further research is warranted to evaluate the responsiveness of FACIT-Fatigue to worsening of these domains.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239746     DOI: 10.3899/jrheum.100799

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

1.  Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial.

Authors:  E Del Fabbro; J M Garcia; R Dev; D Hui; J Williams; D Engineer; J L Palmer; L Schover; E Bruera
Journal:  Support Care Cancer       Date:  2013-05-08       Impact factor: 3.603

2.  Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scale.

Authors:  Zeeshan Butt; Jin-Shei Lai; Deepa Rao; Allen W Heinemann; Alex Bill; David Cella
Journal:  J Psychosom Res       Date:  2012-11-15       Impact factor: 3.006

3.  Indicators and correlates of psychological disturbance in Chinese patients receiving maintenance hemodialysis: a cross-sectional study.

Authors:  Si-Yuan Wang; Xiao-Ying Zang; Jun-Duo Liu; Mei Cheng; Yue-Xian Shi; Yue Zhao
Journal:  Int Urol Nephrol       Date:  2015-01-28       Impact factor: 2.370

4.  An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL.

Authors:  Jin-Shei Lai; Jennifer L Beaumont; Sally E Jensen; Karen Kaiser; David L Van Brunt; Amy H Kao; Shih-Yin Chen
Journal:  Clin Rheumatol       Date:  2016-11-15       Impact factor: 2.980

5.  Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.

Authors:  David Cella; Zeeshan Butt; Hedy Lee Kindler; Charles S Fuchs; Sarah Bray; Arie Barlev; Alan Oglesby
Journal:  Qual Life Res       Date:  2012-06-08       Impact factor: 4.147

6.  Health-related quality of life, fatigue and health utilities in lupus nephritis: A systematic literature review.

Authors:  Saifuddin Kharawala; Gavneet Kaur; Hemlata Shukla; David Alexander Scott; Neil Hawkins; Wen-Hung Chen; Kerry Gairy
Journal:  Lupus       Date:  2022-05-23       Impact factor: 2.858

7.  Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.

Authors:  Elyse E Lower; Atul Malhotra; Victoria Surdulescu; Robert P Baughman
Journal:  J Pain Symptom Manage       Date:  2012-08-20       Impact factor: 3.612

8.  The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Authors:  Alexander Röth; Jun-Ichi Nishimura; Zsolt Nagy; Julia Gaàl-Weisinger; Jens Panse; Sung-Soo Yoon; Miklos Egyed; Satoshi Ichikawa; Yoshikazu Ito; Jin Seok Kim; Haruhiko Ninomiya; Hubert Schrezenmeier; Simona Sica; Kensuke Usuki; Flore Sicre de Fontbrune; Juliette Soret; Alexandre Sostelly; James Higginson; Andreas Dieckmann; Brittany Gentile; Judith Anzures-Cabrera; Kenji Shinomiya; Gregor Jordan; Marta Biedzka-Sarek; Barbara Klughammer; Angelika Jahreis; Christoph Bucher; Régis Peffault de Latour
Journal:  Blood       Date:  2020-03-19       Impact factor: 22.113

9.  Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools.

Authors:  Gemma Strickland; John Pauling; Charlotte Cavill; Neil McHugh
Journal:  Clin Rheumatol       Date:  2012-05-16       Impact factor: 2.980

10.  Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia.

Authors:  Sarah Acaster; Rene Dickerhoof; Kendra DeBusk; Kristine Bernard; William Strauss; Lee F Allen
Journal:  Health Qual Life Outcomes       Date:  2015-05-17       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.